Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
Praxis Precision Medicines revealed expanded analyses from its Phase 3 Essential3 program demonstrating positive results for ulixacaltamide, a novel treatment for essential tremor. Ulixacaltamide has received FDA Breakthrough Therapy Designation. The company will present extensive data from its CNS-focused pipeline at the 2026 AAN Annual Meeting, u…